BioSpace News Archive

Biotech Beach

Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema

Ionis Pharmaceuticals, Inc. announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. under which Otsuka obtains exclusive rights across the Asia-Pacific region for donidalorsen, an investigational RNA-targeted prophylactic medicine for hereditary angioedema.

June 18, 2024
·
5 min read
Ability Biologics Announces the Closing of its US $18 Million Seed Funding Extension toward the Generation of Novel, Highly Targeted Immunomodulators

Ability Biologics announced the final closing of its seed funding, raising a total of $18 million (US), a financing round led by founding investor Amplitude Ventures.

June 18, 2024
·
5 min read
Business

Remix Therapeutics™ Appoints Maria Koehler, M.D., Ph.D., as an Independent Board Director

Remix Therapeutics today announced the appointment of Maria Koehler, M.D., Ph.D., as an independent director to Remix’s Board of Directors.

June 18, 2024
·
2 min read
Deals

Bristol Myers Squibb Announces Dividend - June 18, 2024

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company.

June 18, 2024
·
1 min read
FDA

Elixir Medical’s DynamX Sirolimus-Eluting Coronary Bioadaptor System Granted FDA Breakthrough Device Designation for the Treatment of Symptomatic Ischemic Heart Disease

Elixir Medical’s DynamX Sirolimus-Eluting Coronary Bioadaptor System Granted FDA Breakthrough Device Designation for the Treatment of Symptomatic Ischemic Heart Disease.

June 18, 2024
·
4 min read
Pharm Country

Vyluma Meets with FDA on Atropine Sulfate Ophthalmic Solution 0.01% Under Development to Treat Pediatric MyopiaVyluma Discusses Response to FDA’s Questions and Clarifies Regulatory Pathway for its 505(b)(2) NDA

Vyluma, Inc. (“Vyluma”), a clinical stage pharmaceutical company is focused on the development of ophthalmic treatments for disease states with limited treatment options.

June 18, 2024
·
5 min read
Drug Development

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

Taysha Gene Therapies today announced positive longer-term clinical data from the ongoing REVEAL Phase 1/2 adolescent and adult trial and initial clinical data from the REVEAL Phase 1/2 pediatric trial evaluating TSHA-102 in Rett syndrome.

June 18, 2024
·
16 min read
Deals

Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group

Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, announced it has completed the sale of a 20% equity stake in Shanghai RAAS to Haier Group Corporation and forged a strategic alliance with Haier Group.

June 18, 2024
·
7 min read
Epigenica Unveils Breakthrough Epigenetics Platform, Launches First Commercial ChIP-seq Kit for High-throughput, Multiplex Genome-wide Profiling

Epigenica today unveiled its EpiFinder™ Platform with a patented high-throughput, multiplexing, quantitative ChIP-seq (hmqChIP-seq) technology and launched EpiFinder Genome for comprehensive genome-wide profiling.

June 18, 2024
·
4 min read
Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting

Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will exhibit at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting from June 20-22nd, 2024 at the Rosen Shingle Creek Resort in Orlando, Florida.

June 18, 2024
·
3 min read